Factors VIII and IX gene therapy - Targeted Genetics

Drug Profile

Factors VIII and IX gene therapy - Targeted Genetics

Alternative Names: TgAAV-FVIII

Latest Information Update: 05 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics Corporation
  • Class
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A; Haemophilia B

Most Recent Events

  • 18 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Haemotological Disorders and Gene Therapies pharmacodynamics sections
  • 03 Mar 2003 Suspended - Preclinical for Haemophilia A in USA (unspecified route)
  • 03 Mar 2003 Suspended - Preclinical for Haemophilia B in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top